Children with emotional trauma report using ketamine, which is sold at cheap "pocket-money" prices, to quieten or "shush" their brains.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Trauma-informed support approaches aim to provide effective support for affected individuals by accounting for how past adversity impacts ongoing service interaction and behavior.

Preventing childhood adversity can be achieved by supporting parents, building life skills, challenging harmful social norms, and addressing social pressures on families.

Reducing childhood trauma exposure improves lifelong health while potentially lowering broader societal monetary costs associated with premature death and disease.

The Trauma-informed Wales Framework establishes a societal approach to understanding and responding to trauma, recognizing how past experiences shape adult needs and behavior.

Adults exposed to childhood adversity face heightened risks of mental illness, chronic physical conditions, health-harming behaviors, and poorer education and employment outcomes.

The Department of Health and Human Services is funding early-stage clinical trials of ibogaine to treat opioid addiction and post-traumatic stress disorder through ARPA-H and NIDA.

The Department of Health and Human Services is prioritizing adults with post-traumatic stress disorder as one of two initial populations for federally supported ibogaine research.

Scottish Drugs Forum Chief Executive Kirsten Horsburgh stated that the rise in drug deaths is shaped by wider factors including poverty, trauma, and housing insecurity.

COMP360 is designed to slot directly into existing clinic workflows, utilizing the same multidisciplinary staff that currently monitors Spravato patients.

Johnson & Johnson's Spravato, an inhaled esketamine treatment approved in 2019, established the clinical infrastructure that Compass Pathways plans to utilize for COMP360.

Compass Pathways expects the hourly reimbursement rate for COMP360 administration to be higher than the rate currently paid for Spravato.

Compass Pathways CEO Kabir Nath states that COMP360 will target the estimated 4 million treatment-resistant depression patients who are not currently taking Spravato.

The UK's first ketamine-induced uropathy clinic for children under 16 opened at Alder Hey Children's NHS Foundation Trust in Liverpool in May 2025.

Among the first 60 patients treated at the Alder Hey clinic, 16 had autism, ADHD, or both, one in five had experience in the care system, and 72% had experienced childhood emotional trauma.

An analysis of the first 60 patients at the Alder Hey Children's NHS Foundation Trust clinic showed that approximately two-thirds of the patients were girls, and roughly two-thirds lived in the most deprived areas.

Children as young as 13 are suffering from ketamine-induced uropathy, a severe bladder condition caused by non-prescribed ketamine use that damages the bladder, urinary tubes, and kidneys.

Ketamine-induced uropathy can cause irreversible damage to the bladder wall, including ulceration and fibrosis, which in the most severe cases may require major surgery, bladder removal, or dialysis.

Patients referred to the Alder Hey clinic had been using ketamine for an average of one to two years before referral, with half reporting using other drugs, 48% vaping, and 27% drinking alcohol.

Symptoms of ketamine-induced uropathy in children include frequent urination, loss of bladder control, blood in the urine, and severe pain described by some patients as feeling like "weeing over broken glass."